Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oncopeptides AB (publ) is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological malignancies like multiple myeloma. Founded in 2000 by leading Swedish cancer researchers, the company is headquartered in Stockholm with around 75 employees and a pre-clinical facility in Solna. Its flagship product, Pepaxti (melflufen), a Peptide Drug Conjugate (PDC) based on proprietary technology, received full marketing authorization in Europe for adult patients with triple-class refractory multiple myeloma in combination with dexamethasone. This innovative alkylating agent offers robust efficacy while aiming to reduce treatment burden and preserve quality of life. Oncopeptides maintains a robust pipeline featuring additional PDC candidates and the Small Polypeptide based Killer Engagers (SPiKE) platform, addressing significant unmet needs in oncology. Guided by core values of science, passion, collaboration, courage, and trust, the company fosters an inclusive, entrepreneurial culture committed to advancing patient outcomes through data-driven innovation and global commercialization efforts, primarily in Europe.
kr 0.14
kr 0.00 (-1.30%)
Live · 11:10 PM · Twelve Data
The business is unprofitable at the operating level (-317.62% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 124.7% YoY with margins expanding 581.3pp.
Negative free cash flow of -kr 223M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 83M
▲ +124.7% YoY
Net Income (TTM)
-kr 221M
▲ +12.3% YoY
Op. Margin
-242.77%
▲ +581.3pp YoY
ROIC
-106.42%
▲ +12.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 194M
▲ +14.6% YoY
Op. Cash Flow (TTM)
-kr 186M
▲ +18.3% YoY
Net Debt
kr 57M
Cash & Equiv.
kr 82M
3Y CAGR: +104.2%
Continue Research
Oncopeptides AB (publ) (ONCO.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oncopeptides AB (publ) scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oncopeptides AB (publ) scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -242.8% operating margin and a -106.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ONCO.XSTO's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.